GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CervoMed Inc (NAS:CRVO) » Definitions » Cyclically Adjusted PB Ratio

CervoMed (CervoMed) Cyclically Adjusted PB Ratio : 0.00 (As of Jun. 04, 2024)


View and export this data going back to 1996. Start your Free Trial

What is CervoMed Cyclically Adjusted PB Ratio?

As of today (2024-06-04), CervoMed's current share price is $19.03. CervoMed's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $4,536.78. CervoMed's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for CervoMed's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, CervoMed's highest Cyclically Adjusted PB Ratio was 0.01. The lowest was 0.00. And the median was 0.00.

CRVO's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.745
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

CervoMed's adjusted book value per share data for the three months ended in Mar. 2024 was $0.865. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4,536.78 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


CervoMed Cyclically Adjusted PB Ratio Historical Data

The historical data trend for CervoMed's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CervoMed Cyclically Adjusted PB Ratio Chart

CervoMed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 - -

CervoMed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.01

Competitive Comparison of CervoMed's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, CervoMed's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CervoMed's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CervoMed's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CervoMed's Cyclically Adjusted PB Ratio falls into.



CervoMed Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

CervoMed's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=19.03/4536.78
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CervoMed's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, CervoMed's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.865/131.7762*131.7762
=0.865

Current CPI (Mar. 2024) = 131.7762.

CervoMed Quarterly Data

Book Value per Share CPI Adj_Book
201406 27,789.571 100.560 36,416.292
201409 26,096.951 100.428 34,243.078
201412 23,130.909 99.070 30,767.261
201503 21,366.061 99.621 28,262.470
201506 19,280.000 100.684 25,233.877
201509 11,556.970 100.392 15,169.946
201512 -25.455 99.792 -33.613
201603 1,821.868 100.470 2,389.548
201606 1,525.326 101.688 1,976.649
201609 1,248.478 101.861 1,615.139
201612 998.370 101.863 1,291.556
201703 -2,078.152 102.862 -2,662.309
201706 106.862 103.349 136.255
201709 493.173 104.136 624.075
201712 1,644.462 104.011 2,083.441
201803 661.768 105.290 828.243
201806 607.341 106.317 752.779
201809 465.139 106.507 575.497
201812 346.779 105.998 431.114
201903 287.761 107.251 353.565
201906 258.517 108.070 315.227
201909 216.027 108.329 262.784
201912 45.103 108.420 54.819
202003 38.800 108.902 46.950
202006 38.529 108.767 46.680
202009 33.653 109.815 40.383
202012 29.072 109.897 34.860
202103 39.483 111.754 46.557
202106 36.922 114.631 42.444
202109 28.065 115.734 31.955
202112 25.691 117.630 28.781
202203 22.527 121.301 24.472
202206 19.620 125.017 20.681
202209 17.692 125.227 18.617
202212 -24.480 125.222 -25.761
202303 11.970 127.348 12.386
202306 10.462 128.729 10.710
202309 1.687 129.860 1.712
202312 1.300 129.419 1.324
202403 0.865 131.776 0.865

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CervoMed  (NAS:CRVO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


CervoMed Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of CervoMed's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CervoMed (CervoMed) Business Description

Industry
Traded in Other Exchanges
N/A
Address
20 Park Plaza, Suite 424, Boston, MA, USA, 02216
CervoMed Inc Formerly Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Geographically business activity of the firm functions through the region of the United States.
Executives
Frank Zavrl director C/O PUMA BIOTECHNOLOGY INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Sylvie Gregoire director, 10 percent owner 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
John William Tanner officer: Chief Financial Officer C/O EIP PHARMA, INC., 20 PARK PLAZA, SUITE 424, BOSTON MA 02116
Kelly Blackburn officer: VP, Clinical Development C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Marwan Sabbagh director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
John J Alam director, 10 percent owner, officer: CEO and President 130 WAVERLY STREET, CAMBRIDGE MA 02139
Jeffrey V. Poulton director 300 THIRD STREET, CAMBRIDGE MA 02142
Jill Davidson director 300 EAST MAIN STREET, SUITE 101, CHARLOTTESVILLE VA 22902
Raven Jaeger officer: Chief Regulatory Officer 300 EAST MAIN STREET, SUITE 201, CHARLOTTESVILLE VA 22902
Eric Francois director C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Diana M Lanchoney director 1317 CARLTON AVE, SUITE 200, CHARLOTTESVILLE VA 22902
William Robert Elder officer: GC & Secretary 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Cobuzzi Robert Joseph Jr. director C/O DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Christopher D Galloway officer: Chief Medical Officer 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Jane H Hollingsworth director DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902

CervoMed (CervoMed) Headlines

From GuruFocus

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DFFN, CNXC, LSI

By sperokesalga sperokesalga 04-23-2023

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

By GuruFocusNews GuruFocusNews 06-23-2022